{
    "symbol": "PGEN",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-08 20:21:06",
    "content": " That's exactly the purpose because when we set the first sites and obviously throughout the Phase I arms of the trials, we had generated a substantial amount of data on the manufacturing as well as the assays that are involved and basically the requirements. And I think this allows the vision that we had for this decentralized manufacturing around U.S. and eventually globally, because as we will show in the next few months, we have centers across United States that they have gone through the engineering runs, tech transfers, and they start dosing the patients, which requires comparability of manufacturing."
}